Non-alcoholic Steatohepatitis | Unmet Need | Detailed, Expanded Analysis (US & EU)

Publish date: June 2019

Login to access report

MARKET OUTLOOK

NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Currently, physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. In this report, hepatologists reveal what attributes drive their prescribing and what they are looking for in terms of efficacy, safety, and delivery from future treatments. Using the Target Product Profile (TPP) simulator, we can establish physicians’ preference for emerging drugs and assess if these drugs can capitalize on the untapped NASH space.

QUESTIONS ANSWERED

  • How do hepatologists rate current NASH treatment options such as pioglitazone, vitamin E, and metformin?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and price are needed from new NASH drugs in order to be preferred over current treatment options?
  • How could obeticholic acid, elafibranor, and cenicriviroc meet the expectations of physicians treating NASH?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Three market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European hepatologists and gastroenterologists fielded in April 2019.

Key companies: Takeda, Merck KGaA, Intercept, Genfit.

Key drugs: Pioglitazone, vitamin E, metformin, ursodeoxycholic acid, statins, SGLT-2 inhibitors, GLP-1 receptor agonists.

Table of contents

  • Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in NASH
      • Key Findings: Unmet Need in NASH and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the NASH Market and Emerging Therapy Insights
        • Opportunity: Agent with Demonstrated Efficacy in Improving Fibrosis Stage
        • Opportunity: A Novel Agent That Reduces All-Cause Mortality and Liver-Related Death
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • NASH Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
        • Scenario 3
    • Appendix
      • Bibliography

Author(s): Shreya Saxena, MBA

Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.